State of Alaska Department of Revenue Cuts Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

State of Alaska Department of Revenue lowered its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 2.5% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 30,597 shares of the specialty pharmaceutical company’s stock after selling 786 shares during the quarter. State of Alaska Department of Revenue’s holdings in Supernus Pharmaceuticals were worth $1,002,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of SUPN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Supernus Pharmaceuticals by 3.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,563 shares of the specialty pharmaceutical company’s stock valued at $1,033,000 after purchasing an additional 1,083 shares in the last quarter. Two Sigma Advisers LP boosted its position in shares of Supernus Pharmaceuticals by 14.7% in the fourth quarter. Two Sigma Advisers LP now owns 7,800 shares of the specialty pharmaceutical company’s stock worth $282,000 after buying an additional 1,000 shares during the period. Smartleaf Asset Management LLC grew its stake in shares of Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 870 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of Supernus Pharmaceuticals by 6.2% during the 4th quarter. Envestnet Asset Management Inc. now owns 59,970 shares of the specialty pharmaceutical company’s stock valued at $2,169,000 after buying an additional 3,495 shares during the period. Finally, SG Americas Securities LLC raised its holdings in shares of Supernus Pharmaceuticals by 63.6% during the 1st quarter. SG Americas Securities LLC now owns 17,671 shares of the specialty pharmaceutical company’s stock valued at $579,000 after buying an additional 6,867 shares during the period.

Supernus Pharmaceuticals Trading Down 0.1%

Shares of SUPN stock opened at $31.20 on Friday. The firm has a fifty day simple moving average of $32.17 and a 200-day simple moving average of $34.06. The company has a market capitalization of $1.75 billion, a PE ratio of 28.11 and a beta of 0.71. Supernus Pharmaceuticals, Inc. has a twelve month low of $25.55 and a twelve month high of $40.28.

Wall Street Analyst Weigh In

Separately, Wall Street Zen cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, June 21st.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.